ArticleJournal of clinical medicine2026

TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.

Keigo KobayashiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.